Open in PodwiseOpen

Podcast cover

STAT · Science

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Episodes

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

318: Drug pricing drops & psychedelics under fire

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

313: Biotech layoffs, founder-focused VC, & a big pharma exit

312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

308: An ASCO preview & another Duchenne trial failure

307: More tumult at BIO & coercive care for sickle cell patients

306: Live! From the STAT Breakthrough Summit West

305: Everything you need to know about H5N1 bird flu

304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

302: Vertex's big deal, biotech's red numbers, & an industry history lesson

301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

Page 6

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise